Case of nivolumab-induced sclerosing cholangitis: lessons from long-term follow-up

Nivolumab is an immune checkpoint inhibitor used to treat multiple solid-organ malignancies. While many of its immune-related adverse events are well established, nivolumab-induced sclerosing cholangitis remains poorly characterised, with no defined diagnostic criteria. Moreover, data regarding long...

Descripción completa

Detalles Bibliográficos
Autores principales: McClure, Tess, Cui, Wanyuan, Asadi, Khashayar, John, Thomas, Testro, Adam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7484867/
https://www.ncbi.nlm.nih.gov/pubmed/32912846
http://dx.doi.org/10.1136/bmjgast-2020-000487

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7484867/
https://www.ncbi.nlm.nih.gov/pubmed/32912846
http://dx.doi.org/10.1136/bmjgast-2020-000487

Ejemplares similares